Table 2.

T cells with increased numbers of surface thiols become effector cells

TreatmentBloodSpleenInguinal LNsDraining LNsThymusJoint
PBS, day 724.0 ± 20.51* 0.43 ± 1.047.96 ± 5.9329.69 ± 31.2515.28 ± 2.375.28 ± 1.71
GSH, day 755.67 ± 5.5123.14 ± 9.34 53.75 ± 3.07 77.79 ± 17.20 19.55 ± 3.717.27 ± 3.32
PBS, day 126.02 ± 2.0822.74 ± 7.7216.50 ± 18.1126.46 ± 18.475.23 ± 1.0413.74 ± 2.62
GSH, day 1220.85 ± 5.8727.70 ± 5.6858.13 ± 6.77 9.79 ± 5.603.29 ± 0.3427.33 ± 3.67
  • Concanavalin A cultured T cells from spleens from immunized DA.Ncf1 E3 rats (RT1Aa+) were treated with PBS or GSH before i.v. injection into irradiated (6 Gy) allogeneic DA.1I rats (RT1Aa−). After 7 and 12 days, RT1Aa+-positive cells were found in draining (mediastinal) LNs, inguinal LNs, spleen, thymus, and arthritic joints. The percentage of RT1Aa+ CD4+TCR+ cells amongst CD4+TCR+ cells is shown ±SD. GSH-treated cells proliferated significantly more than PBS-treated cells in draining and inguinal LNs and homed more to the joints. Only rats that received GSH-treated cells developed arthritis. Mean ± SD is shown for four to five rats per group.

  • *Percentage of RT1Aa+ CD4+TCR+ cells amongst all CD4+TCR+ cells.

  • P < 0.05.